JM 3100

Subscribe to Selected New Research on JM 3100

90 relevant articles (5 outcomes, 10 trials/studies) found for this Bio-Agent

Description: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2; partial structure given in first source

Also Known As:

1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate; 1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate; AMD 3100; AMD 3329; AMD-3100; AMD-3329; AMD3100; JM-3100; JM3100; bicyclam

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

JM 3100: 90

Experts

1.	Calandra, Gary: 5 articles (08/2007 - 03/2004)
2.	Badel, Karin: 3 articles (08/2007 - 03/2004)
3.	Bridger, Gary J: 3 articles (10/2004 - 04/2002)
4.	Broxmeyer, Hal E: 2 articles (09/2008 - 04/2004)
5.	Bridger, G: 2 articles (02/2008 - 10/2001)
6.	Schols, Dominique: 2 articles (10/2004 - 04/2002)
7.	Henson, Geoffrey W: 2 articles (10/2004 - 04/2004)
8.	Clapp, D Wade: 1 article (09/2008)
9.	Li, Yan: 1 article (09/2008)
10.	Pulliam, Anna C: 1 article (09/2008)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 08/28/2006 - "AMD3100 is an effective mobilizer of hematopoietic stem cells and is being investigated in clinical trials in multiple myeloma and non-Hodgkins lymphoma patients" 03/15/2004 - "We performed a phase I study assessing the safety and clinical effects of AMD3100 in patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL)" 06/01/2005 - "Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma." 03/15/2004 - "Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma." 08/01/2007 - "Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients." Get all the results and reference details, order at left...
2.	Lymphoma (Lymphomas) 08/01/2007 - "AMD3100 was generally safe and improved PBSC and DC cell mobilization with no apparent contamination of lymphoma cells." 08/01/2007 - "We initiated a phase II study of 11 refractory or relapsed non-Hodgkin's lymphoma (NHL) patients, receiving 16 microg/kg daily of G-CSF for 4 days followed by 240 microg/kg of AMD3100 given subcutaneously on a new schedule of 9-10 h before apheresis collection on day 5. Our aims were to assess the effect of AMD3100 on the mobilization of CD34+ cells, dendritic cells (DCs) and lymphoma cells" Get all the results and reference details, order at left...
3.	Infection 01/01/2008 - "The CXCR4 antagonist AMD3100 is also effective against X4 HIV-1 infected PBMCs in our model with IC50 comprised between 4 nM and 640 nM. HIV-1 entry inhibitors are less efficient to block cell-to-cell virus transmission than cell-free HIV-1 infection of PBMCs and CCR5 antagonists do not prevent PBMC infection by dual tropic HIV-1 in contrast to cell-to-cell infection in our model" 12/01/2008 - "While infection by most virus strains was completely blocked by AMD3100, we identified several R5X4 and X4 isolates that exhibited plateau effects: as the AMD3100 concentration was increased, virus infection and membrane fusion diminished to variable degrees" 12/01/2008 - "We screened a panel of R5X4 and X4 human immunodeficiency virus type 1 (HIV-1) strains for their sensitivities to AMD3100, a small-molecule CXCR4 antagonist that blocks HIV-1 infection via this coreceptor" 11/01/2004 - "Infection of AML14.3D10-CCR3 cells by HTLV-III(B) was completely inhibited by AMD3100, indicating that X4 HIV-1 enters the AML14.3D10-CCR3 cell line by using the CXCR4 coreceptor exclusively" 11/01/2004 - "Furthermore, AMD3100 treatment failed to prevent infection of known CD4+ CXCR4+ T-cell lines (MT-2 and CEM) by the 93US143-T8 isolate" Get all the results and reference details, order at left...
4.	Neoplasms (Cancer) 01/15/2008 - "The tumor number of the AMD3100 group was (64.6 +/- 8.2), significantly lower than that of the control group [(103 +/- 12.4), P < 0.01]" 01/15/2008 - "BALB/c nu/nu female nude mice underwent intraperitoneal injection of NUGC4 cells, and then with PBS or AMD3100, small molecular specific antagonist, one day after the cancer cell injection once a day for 2 weeks" 12/15/2007 - "Moreover, AMD3100 effectively reduced tumor growth in nude mice inoculated with different ATC cells" 11/01/2007 - "RESULTS AND DISCUSSION: The tumor volume was reduced by 27.6% in mice administered AMD 3100 compared with the control group (p < 0.02)" 03/01/2006 - "Early recruitment of adoptively transferred OVA-specific CTL into B16/OVA tumors expressing high levels of CXCL12 was significantly reduced in comparison to B16/OVA tumors, and this reduction was reversed when tumor-specific CTLs were pretreated with the specific CXCR4 antagonist, AMD3100" Get all the results and reference details, order at left...
5.	Neoplasm Metastasis (Metastasis) 12/01/2004 - "Inhibiting CXCR4 with RNAi, or the specific antagonist AMD3100, substantially delayed the growth of 4T1 cells in the lung, although neither RNAi nor AMD3100 prolonged overall survival in mice with experimental lung metastases" 04/21/2008 - "AIM: To investigate the effect and mechanism of blockade of the CXC chemokine receptor-4 (CXCR4) signaling pathway by AMD3100, a small non-peptide CXCR4 inhibitor, on invasion and metastasis of colorectal cancer cells in vitro" 04/15/2006 - "CONCLUSIONS: These findings indicate that CXCR4 is expressed and active in human melanoma metastases, suggesting that active inhibitors such as AMD3100 may be experienced in human melanoma." 07/01/2007 - "Under the present conditions, AMD3100, a CXCR4 antagonist, significantly inhibited the lung metastasis of the SDF-1 transfectant, ameliorated body weight loss, and improved the survival rate of tumor-bearing nude mice" 04/21/2008 - "AMD3100 inhibited invasion and metastasis activity of the colorectal cancer cell line SW480 through down-regulation of VEGF and MMP-9 expression." Get all the results and reference details, order at left...
54 Diseases and 90 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Granulocyte Colony-Stimulating Factor (G-CSF)
2.	Chemokine CXCL12
3.	Carmustine (FIVB)
4.	CXCR4 Receptors (CXCR4 Receptor)
5.	Phosphonic Acids (Phosphonates)
6.	Bleomycin (Blenoxane)
7.	Radioisotopes (Radionuclides)
8.	Carbon Monoxide
9.	pinacolyl methylphosphonic acid
10.	JM 3100
61 Drugs and Important Bio-Agents and 46 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Hematopoietic Stem Cell Mobilization
2.	Blood Component Removal (Apheresis)
3.	Stem Cell Transplantation
4.	Transplants (Transplant)
5.	Homologous Transplantation (Allograft)
9 Therapies and Procedures and 11 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>